Abits
ABTS
Argo Blockchain
ARBK
CATHEDRA BITCOIN INC
CBTTF
Canaan
CAN
The9 Ltd
NCTY
US Stock MarketDetailed Quotes
COGT Cogent Biosciences
- 7.710
- -0.030-0.39%
Close Dec 30 16:00 ET
- 8.090
- +0.380+4.93%
Post 20:01 ET
851.66MMarket Cap-3.11P/E (TTM)
7.750High7.450Low1.01MVolume7.670Open7.740Pre Close7.71MTurnover1.58%Turnover RatioLossP/E (Static)110.46MShares12.61052wk High4.17P/B495.02MFloat Cap4.28052wk Low--Dividend TTM64.21MShs Float174.200Historical High--Div YieldTTM3.87%Amplitude1.904Historical Low7.628Avg Price1Lot Size
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Cogent Biosciences Stock Forum
based on a quick AI research:
AdvSM is very rare. Estimated 5,000-10,000 patients in US. Limited total market size.
Based on the recent clinical data, here are Cogent Biosciences' potential advantages:
1. Efficacy Advantages:
◦ 83% ORR (mIWG criteria)
◦ 100% ORR (PPR criteria)
– Higher response rate at optimal dose (100mg BID):
– Quick response time (2.2 months)
– Potentially better than existing treatments
1. Potential Market Differentiati...
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Positive
Strong 83% ORR in 100 mg BID dose cohort
94% of patients achieved ≥50% reduction in serum tryptase levels
Rapid median time to response of 2.2 months
82% progression-free survival rate at 24 months
100% of evaluable patients achieved ≥50% reduction in bone marrow mast cell burden
Negative
12 pat...
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID
88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID
Median time to response 2.2 months with median duration of response and median PFS not yet reach...
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...
GlobeNewswire· 30 mins ago
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
No comment yet